Roy Louis Maute is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of biotherapeutics, holding a total of 10 patents. His work primarily focuses on enhancing immune responses and developing novel therapeutic agents.

Latest Patents

Among his latest patents, Maute has developed high affinity PD-1 agents and methods of use. These agents comprise at least one amino acid change relative to a wild-type PD-1 protein and exhibit increased affinity for PD-L1. This innovation aims to modulate the activity of immune cells in mammals by blocking the physiological binding interaction between PD-1 and its ligands. Another notable patent involves methods and compositions for inducing phagocytosis of MHC class I positive cells. This work addresses the treatment of cancer and intracellular pathogen infections, providing methods to predict an individual's resistance to anti-CD47/SIRPA agents.

Career Highlights

Maute has worked with esteemed institutions such as Leland Stanford Junior University and Ab Initio Biotherapeutics, Inc. His career reflects a commitment to advancing therapeutic strategies that enhance immune system functionality.

Collaborations

Throughout his career, Maute has collaborated with notable colleagues, including Aaron Michael Ring and Andrew Curtis Kruse. These partnerships have contributed to the development of innovative solutions in the field of biotherapeutics.

Conclusion

Roy Louis Maute's contributions to the field of biotherapeutics through his patents and collaborations highlight his role as a leading inventor. His work continues to influence the development of novel therapeutic agents aimed at improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.